Skip to content

Petros Pharmaceuticals, Inc.

Public company
Headquarters
NEW YORK, New York
Ticker
PTPI
CIK
0001815903

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

4
0 appointments, 4 departures

Last event

Sep 30, 2026
Executive departureExecutive Chairman departs: Joshua N. Silverman

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
Executive ChairmanJoshua N. SilvermanSep 30, 2026Departed
DirectorBruce T. BernsteinSep 30, 2026Departed
President and Chief Commercial OfficerFady BoctorSep 30, 2026Departed

Same industry and state, with recent events.

  1. Executive departure

    Executive Chairman departs: Joshua N. Silverman

    Joshua N. Silverman, Executive Chairman of Petros Pharmaceuticals, Inc., resigns the role, effective September 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Executive Chairman

    Source: SEC 8-K, filed Sep 30, 2026
  2. Executive departure

    Director departs: Bruce T. Bernstein

    Bruce T. Bernstein, Director of Petros Pharmaceuticals, Inc., resigns the role, effective September 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Director

    Source: SEC 8-K, filed Sep 30, 2026
  3. Executive departure

    Director departs: Wayne R. Walker

    Wayne R. Walker, Director of Petros Pharmaceuticals, Inc., resigns the role, effective September 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Director

    Source: SEC 8-K, filed Sep 30, 2026
  4. Executive departure

    President and Chief Commercial Officer departs: Fady Boctor

    Fady Boctor, President and Chief Commercial Officer of Petros Pharmaceuticals, Inc., leaves the role, effective September 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: President and Chief Commercial Officer

    Source: SEC 8-K, filed Sep 30, 2026

Last verified Nov 8, 2026